Videos | Bringing pharma’s top innovators to your screen

Skip to main content

Sunday 19 July 2026

BlueSky linkedin youtube

header links

Get Newsletters
Media Kit

Pharmaphorum menu first category

News
Views & Analysis
Deep Dive
Webinars
Podcasts
Videos
Spotlight on
Events

close

SECTION

News
Views & Analysis
Deep Dive
Webinars
Podcasts
Videos
White Papers
Events

Channels

Channels

Sales & Marketing
R&D
Digital
Market Access
Oncology
Patients
Spotlight On

Channels

Sales & Marketing
R&D
Digital
Market Access
Oncology
Patients
Spotlight On

SUB NAVIGATION

Live Coverage
Partner Content
About us
Work for us
Contribute
Contact us
Advertise

Newsletters and Deep Dive digital magazine

youtube linkedin BlueSky

Oncology

ASCO 2026: Astellas innovates in ADCs and T Cell engagers, with Tony Jarkowski

ASCO 2026: Astellas innovates in ADCs and T Cell engagers, w...

Oncology

ASCO 2026: Pluvicto shows consistency, with Dr Fred Saad

ASCO 2026: Pluvicto shows consistency, with Dr Fred Saad

In a conversation at ASCO 2026, Dr Fred Saad of the University of Montreal shared some insights from a subgroup analysis of Pluvicto

Oncology

ASCO 2026: All about DNA damage response, with Luke Piggot

ASCO 2026: All about DNA damage response, with Luke Piggot

Luke Piggot, a principal scientist at Debiopharm, shares some recent data and news about the company's work in DNA damage repair inhibitors.

Patients

ASCO 2026: New hope in AL amyloidosis, with Dr Hans Lee

ASCO 2026: New hope in AL amyloidosis, with Dr Hans Lee

A phase 1/2 trial in AL amyloidosis saw 100% of patients obtaining at least a very good partial response with 90% obtaining a complete response.

Oncology

ASCO 2026: Three ADC approvals in five days, with Ken Keller and John Tsai

ASCO 2026: Three ADC approvals in five days, with Ken Keller...

At ASCO 26, Daiichi Sankyo leaders Ken Keller and John Tsai chatted with pharmaphorum about their big year of oncology launches, halfway in.

Oncology

health-innovators

Health Innovators – Dr. Jack Hoppin and Dr. John Babich

A few weeks ago, pharmaphorum Editor-in-Chief Jonah Comstock popped in on Ratio Therapeutics co-founders Dr. Jack Hoppin and Dr. John Babich at their WeWork coworking

Digital

Health Innovators FH 2022

Health Innovators – Monique Levy

In this bonus interview from Frontiers Health 2022, provided by our partners at Healthware, pharmaphorum Founder Paul Tunnah chats with Woebot Health Chief Business Officer Monique Levy abo

Views & Analysis

Health Innovators FH 2022

Health Innovators – Paolo Borella

In our final interview from Frontiers Health 2022, pharmaphorum Editor in Chief Jonah Comstock sits down with Paolo Borella, who runs the new VITA digital health accelerator in Italy.

Load more results

Sales & Marketing

Sales & Marketing

Interview with Craig Ackerman Reuters at Pharma USA 2026

Biotech is back, with Craig Ackerman

In Philadelphia last month, pharmaphorum spoke with Craig Ackerman, a partner at the Alexander Group, about launches, AI best practices, and more.

Sales & Marketing

Interview at JPM26 with Helen Sabzevari and Greg Skalicky

Rewiring commercialisation to meet the moment, with Helen Sa...

At the Informa Biotech Showcase at JPM2026, EVERSANA President Greg Skalicky and Helen Sabzevari, CEO of Precigen, discuss new commercialisation.

Digital

Digital

Interview at Reuters Pharma EU with Florian Schnappauf, Veeva

From data to deployment: Navigating AI adoption in pharma wi...

Explore our video interview for expert tips on AI adoption in pharma, featuring Veeva.

Digital

Inizio Ignite, STEM AI video feature image

Sponsored

STEM AI: Delivering intelligent data-led HCP interactions

In a new sponsored video, pharmaphorum spoke with experts from STEM, an Inizio Ignite company, about STEM AI

Market Access

Patients

Interview with Matt Wadyka at Reuters Pharma USA 2026

Making direct-to-patient work, with Matt Wadyka

Matt Wadyka, chief client strategy officer at Inizio Medical, spoke to pharmaphorum about the ins and outs of direct-to-patient programmes in pharma.

Market Access

Interview with Marjorie Sidhoum at BIO Europe 2026

BIO-Europe Spring 2026: In conversation with Marjorie Sidhou...

Marjorie Sidhoum, vice president of business development & corporate communication at Kainova Therapeutics, discusses their immuno-oncology pipeline.

Editor's Picks

Vertex buys Crinetics for $10bn in endocrinology drive

UK first in Europe to clear Boehringer's IPF drug Jascayd

NICE aims to cut funding for Amgen lung cancer drug Lumykras

Island Pharma drug cleared for Bundibugyo Ebola use

NICE backs NHS use of non-invasive endometriosis tests

Newsletters and Deep Dive
digital magazine

Get Newsletters

Get in-depth news, opinions, and features on pharma and healthcare sent straight to your inbox

Oncology

Oncology

ASCO 2026: Astellas innovates in ADCs and T Cell engagers, with Tony Jarkowski

ASCO 2026: Astellas innovates in ADCs and T Cell engagers, w...

Oncology

ASCO 2026: All about DNA damage response, with Luke Piggot

ASCO 2026: All about DNA damage response, with Luke Piggot

Luke Piggot, a principal scientist at Debiopharm, shares some recent data and news about the company's work in DNA damage repair inhibitors.

Oncology

ASCO 2026: Three ADC approvals in five days, with Ken Keller and John Tsai

ASCO 2026: Three ADC approvals in five days, with Ken Keller...

At ASCO 26, Daiichi Sankyo leaders Ken Keller and John Tsai chatted with pharmaphorum about their big year of oncology launches, halfway in.

Patients

Patients

ASCO 2026: New hope in AL amyloidosis, with Dr Hans Lee

ASCO 2026: New hope in AL amyloidosis, with Dr Hans Lee

A phase 1/2 trial in AL amyloidosis saw 100% of patients obtaining at least a very good partial response with 90% obtaining a complete response.

Patients

ASCO 2026: Quality of life, not just quantity, with Dr Harold Keer

ASCO 2026: Quality of life, not just quantity, with Dr Harol...

Dr Harold Keer, chief medical officer at Taiho Oncology, goes in-depth about why his company places such an emphasis on oral formulations.

Patients

Interview with Matt Wadyka at Reuters Pharma USA 2026

Making direct-to-patient work, with Matt Wadyka

Matt Wadyka, chief client strategy officer at Inizio Medical, spoke to pharmaphorum about the ins and outs of direct-to-patient programmes in pharma.

R&D

R&D

Happy patient and HCP

Sponsored

IQVIA on reducing complexity and workload for clinical trial...

R&D

hVIVO Future of RSV research

Sponsored

Rethinking clinical research: The case for human challenge t...

R&D

Interview at LSX 2026 with Paulo Neves

LSX2026: Endogenous tissue restoration in vascular disease –...

Paulo Neves, CMO of Xeltis, discusses transformative implants that enable the natural creation of living and long-lasting vessels.

Editor's Picks

Vertex buys Crinetics for $10bn in endocrinology drive

UK first in Europe to clear Boehringer's IPF drug Jascayd

NICE aims to cut funding for Amgen lung cancer drug Lumykras

Island Pharma drug cleared for Bundibugyo Ebola use

NICE backs NHS use of non-invasive endometriosis tests

News

Dr Anker Lundemose

UK's Mission divests kidney drug to Dimerix for $292m

Mission Therapeutics has struck a deal to out-license a drug for acute kidney injury to Australia's Dimerix, sharpening its focus on CNS diseases.

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png

Digital

Discover a new era of healthcare panel engagement

Sponsored

Discover a new era of healthcare panel engagement: Grounded ...

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.

Pharmaphorum Menu

Digital
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Market Access
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Oncology
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Patients
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
R&D
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Sales & Marketing
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Spotlight on

Sign up for email newsletters and Deep Dive

Get Newsletters

youtube linkedin BlueSky

About us Advertising Contact us

Contribute Cookie Policy Privacy Policy

Terms & Conditions Work for us

The rights of trademark owners are acknowledged. Website and content copyright © 2009-2026, pharmaphorum media limited or its licensors; all rights reserved. pharmaphorum – an EVERSANA company

The rights of trademark owners are acknowledged. Website and content copyright © 2009-2026, pharmaphorum media limited or its licensors; all rights reserved. pharmaphorum – an EVERSANA company